UNITED LAB (03933) plans to allocate up to HK$200 million to repurchase shares.
Pharmaceutical Federal (03933) announced that it intends to exercise its power under the general mandate given by the company's shareholders at the annual general meeting held on June 25, 2025, to repurchase the company's ordinary shares, with a maximum investment of 200 million Hong Kong dollars to repurchase shares on the open market at the appropriate time. The company will later cancel the repurchased shares.
UNITED LAB (03933) announces that it plans to exercise its general authorization to repurchase ordinary shares of the company following approval by the company's shareholders at the annual general meeting on June 25, 2025, with a maximum expenditure of HK$200 million to repurchase shares on the open market at an appropriate time. The company will subsequently cancel the repurchased shares.
The proposed share repurchase will be funded by internal cash. The Board is confident in the company's strong financial position and believes that the proposed share repurchase is in the overall interest of the company and its shareholders. The proposed share repurchase and subsequent cancellation of the repurchased shares can enhance the value of the shares and improve shareholder returns.
Related Articles
On June 11th, OmniVision Integrated Circuits Group, Inc. (Stock Code: 00501) spent 101 million RMB to repurchase 1.1774 million A-shares.
KINDSTAR GLOBAL (09960) spent 19,300 Hong Kong dollars to repurchase 19,000 shares on June 11th.
BRCM's SZSE IPO has been accepted, focusing on products related to brain-computer interfaces.
On June 11th, OmniVision Integrated Circuits Group, Inc. (Stock Code: 00501) spent 101 million RMB to repurchase 1.1774 million A-shares.
KINDSTAR GLOBAL (09960) spent 19,300 Hong Kong dollars to repurchase 19,000 shares on June 11th.
BRCM's SZSE IPO has been accepted, focusing on products related to brain-computer interfaces.
RECOMMEND
